All News

A study published January 6, 2022 showed that COVID-19 vaccinations may temporarily cause changes to the timing of menstruation.

What you missed this week in women's health

An experimental blood test uses plasma cell-free RNA (cfRNA) to accurately predict preeclampsia as early as 16 weeks

To the investigators’ surprise, routine perinatal visits had the greatest impact on PROM in pregnant women with VVC.

Contemporary OBGYN® mourns the passing of Michael J. Hennessy Sr, chairman and CEO of MJH Life Sciences™.

The Society for Maternal-Fetal Medicine has announced its upcoming 2022 annual meeting will now be virtual.

A cross-sectional analysis of the Boston Birth Cohort (BBC) from 1998 to 2016 has found that maternal nativity and duration of United States residence were linked to preeclampsia among non-Hispanic Black women, but not among Hispanic and non-Hispanic White women, after adjusting for sociodemographic and cardiovascular risk factors.

Being Non-Hispanic (N-H) Asian is a significant influencing factor for the number of gastrointestinal (GI) symptoms and the severity scores of GI symptoms, according to a study of 4 major racial/ethnic groups of midlife women in the United States.

While it has been nearly 50 years since vaginal dilators were introduced as a therapy to decrease VS, the medical community still knows very little about the potential impact on long term outcomes.

While sacrocolpopexy has been the gold standard for the anatomical correction of pelvic organ prolapse for more than three decades, it is a technically challenging procedure that results in dividing the pelvis by mesh material and often requires extensive bowel manipulation.

Lactobacilli are the presiding members of the healthy human vaginal microbiota and are considered the first defense line from pathogen infection, including vulvovaginal candidiasis (VVC), whereas biofilm is the predominant microbial growth form in nature.

COVID-19 updates and news to know as of January 3, 2022.

A home kit to detect urinary tract infections (UTIs) like Candida albicans from vaginal fluids on sanitary napkins and tampons could soon enter the clinical phase.

The use of hair dyes, bleach, relaxers, and mousse was associated with lower levels of sex steroid hormones in pregnant women, according to a new Rutgers study.

A look at what's coming to Contemporary OB/GYN® this week

Women are less likely to be diagnosed with bladder cancer, but that does not make the disease any less fatal for this population of patients.

Each year, the Medical Economics® team surveys their audience to find out what big challenges practitioners faced. By far, the top answer was “administrative burdens,” including staffing, prior authorizations and electronic health records (EHRs). Let's take a closer look at what these burdens entail to help physicians get ready for whatever challenges 2022 will bring.

The moves bring two new weapons to the toolbox for physicians fighting the pandemic.

Researchers highlight the need for early interventions.

Pandemic’s impact could worsen gender divide in income and career prospects, study finds.

Two possible explanations for declining contentment with live video calls as a form of care delivery.

Apretude is approved for use in at-risk adults and adolescents to reduce the risk of sexually acquired HIV.

Investigators of the SWOG S1007 RxPONDER trial found a statistically significant improvement in invasive disease-free survival and distant relapse-free survival in premenopausal women who received adjuvant chemotherapy.

“I think discussing it and talking about the different techniques out there [is important],” says Svetlana Avulova, MD.

It's been a busy week for the Contemporary OB/GYN® team.

Contemporary OB/GYN® board members share their insights into the most influential articles of the year.

CDC data shown to overstate US vaccination rates; school-based cognitive behavioral therapy for overwhelmed children; Moderna to develop Omicron-specific COVID-19 booster dose.

Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.